Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study

Oral Oncology

Volumn 39, Issue 7, 2003, Pages 724-727

  Haddad, Robert ^a   Colevas, A Dimitrios ^b   Krane, Jeffrey F ^c   Cooper, Dennis ^d   Glisson, Bonnie ^e   Amrein, Philip C ^f   Weeks, Linda ^a   Costello, Rosemary ^a   Posner, Marshall ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d YALE CANCER CENTER   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Her2 Neu; Herceptin; Salivary gland tumors

Indexed keywords

ANTINEOPLASTIC AGENT; TRASTUZUMAB;

ADENOSQUAMOUS CARCINOMA; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SCREENING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FEMALE; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; METASTASIS; ONCOGENE NEU; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SALIVARY GLAND CARCINOMA; TREATMENT OUTCOME;

EID: 0042703590     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-8375(03)00097-6     Document Type: Article

References (17)

1. O'Brien C.J., Soong S.J., Herrera G.A., Urist M.M., Maddox W.A. Malignant salivary tumors - analysis of prognostic factors and survival. Head Neck Surg. 9:1986;82-92.
2. Spiro R.H. Salivary neoplasms. overview of a 35-year experience with 2,807 patients Head Neck Surg. 8:1986;177-184.
3. Alvi A.M.E., Carrau R. Malignant tumors of the salivary glands. 3rd ed:1996;W.B. Saunders, Philadelphia.
4. Spiro R.H. Management of malignant tumors of the salivary glands. Oncology (Huntingt). 12:1998;671-680. [discussion 83].
5. Press M.F., Pike M.C., Hung G.et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland. correlation with poor prognosis Cancer Res. 54:1994;5675-5682.
6. Slamon D.J., Godolphin W., Jones L.A.et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712.
7. Gullick W.J., Love S.B., Wright C.et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer. 63:1991;434-438.
8. Hetzel D.J., Wilson T.O., Keeney G.L., Roche P.C., Cha S.S., Podratz K.C. HER-2/neu expression. a major prognostic factor in endometrial cancer Gynecol Oncol. 47:1992;179-815.
9. Giannoni C., el-Naggar A.K., Ordonez N.G.et al. c-erbB-2/neu oncogene and Ki-67 analysis in the assessment of palatal salivary gland neoplasms. Otolaryngol Head Neck Surg. 112:1995;391-398.
10. Glisson B.C.A., Krane J.et al. Over-expression of her2/neu in carcinomas of the salivary gland:dependance on histologic subtype. AACR Proceedings. 43:2001.
11. Creagan E.T., Woods J.E., Schutt A.J., O'Fallon J.R. Cyclophosphamide, adriamycin, and cis-diamminedichloroplatinum (II) in the treatment of advanced nonsquamous cell head and neck cancer. Cancer. 52:1983;2007-2010.
12. Dreyfuss A.I., Clark J.R., Fallon B.G., Posner M.R., Norris C.M. Jr., Miller D. Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer. 60:1987;2869-2872.
13. Venook A.P., Tseng A. Jr., Meyers F.J.et al. Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J Clin Oncol. 5:1987;951-955.
14. Airoldi M., Pedani F., Succo G.et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer. 91:2001;541-547.
15. Jennings T., Li Y., Pinto H., Kies M., Mansour E., Forastier A. Phase II trial of paclitaxel in advanced or metastatic salivary gland malignancies. an Eastern Cooperative Oncology Group Study [Abstract] Proceedings of American Society of Clinical Oncology. 20:2001;236a.
16. Baselga J., Tripathy D., Mendelsohn J.et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 14:1996;737-744.
17. Slamon D.J., Leyland-Jones B., Shak S.et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344:2001;783-792.